iGene to launch digital autopsy network in Australia
By Digital News Asia January 22, 2016
- Partnership with GCS Agile will also explore the NZ market
- iGene’s technology allows full, non-invasive digital post-mortems
MALAYSIAN bioinformatics company iGene Sdn Bhd said it has signed a memorandum of collaboration with GCS Agile Australia to establish a network of digital autopsy facilities in Australia, following a similar launch in the United Kingdom in 2013.
The partnership with GCS Agile will also explore a possible move into New Zealand, iGene said in a statement.
The company’s digital autopsy technology involves a three-dimensional scan of the body using a CT scanner, and visualisation software which allows pathologists to conduct a full, non-invasive digital post-mortem.
“Digital autopsy is more than just a technological innovation; we believe it represents a tremendous humanitarian step forward in establishing the cause of unnatural death in a humane manner,” said iGene chief executive officer Matt Chandran.
The collaboration with GCS Agile aims to increase operational efficiency and set a new standard of performance in the provision of Crime Scene Investigation (CSI) and post-mortem services, totalling approximately 15,500 cases per year in Australia, iGene said.
Ultimately this will extend to cover the digitisation of all deaths in Australia, currently about 150,000 annually, providing a national medical record for the purposes of preventative health and education, the company added.
“We are excited by this opportunity to collaborate with iGene to accelerate our mission of dramatic social and economic impact by leveraging big data, to achieve our vision of a world of perfect data where you can predict the future and optimise decisions on the edge,” said GCS Agile founder and chief executive officer Gerry Carcour.
“Specifically, digital autopsies will revolutionise the forensic, medico-legal and educational sectors,” he added.
iGene was established to spearhead the development of a new subsector in forensic medicine and is an investee company of Malaysia Venture Capital Management Bhd (Mavcap) and Agensi Inovasi Malaysia (AIM).
“The company has achieved tremendous brand recognition around the world for its ground-breaking innovation,” said Susila Devi, deputy chief executive officer of Malaysia External Trade Development Corp, who witnessed the signing ceremony between iGene and GCS Agile.
“Indeed, this made-in-Malaysia technology is a milestone for innovation in the country,” she added.
iGene conquers UK, eyes Middle East and US next
Digerati50: The best still to come from Matt Chandran
Frustration the trigger for success at iGene
For more technology news and the latest updates, follow us on Twitter, LinkedIn or Like us on Facebook.